Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 21 |
| Active Pipeline (Recruiting Now) | 11 (6) |
| Completed vs Stopped Early | 6 / 4 (19.1%) |
| Median Closed Actual Enrollment | 75 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Northwestern Memorial and Lurie Cancer Center | Chicago, IL | 12 |
| Mayo Clinic Rochester | Rochester, MN | 10 |
| Stanford Health Care and Stanford Cancer Institute | Stanford, CA | 9 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06524882 | Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age | Phase III | RECRUITING |
| NCT04378790 | A Randomized Trial to Evaluate Sequential vs Simultaneous Patching | Phase III | RECRUITING |
| NCT06790784 | Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR | Phase III | RECRUITING |
| NCT05844982 | Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to | Phase III | RECRUITING |
| NCT06380517 | Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age | Phase III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Jaeb Center for Health Research Interactive Dossier, benchmark peers in Endocrinology, Obesity, and Metabolic, or review the Healthcare Price & Patent Cliff Crosswalk.